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ABSTRACT
Objective. Osteoarthritis (OA) is a 
chronic rheumatic disease character-
ised by progressive cartilage destruc-
tion mediated by cytokines and other 
molecules. Chondrocyte activity and 
metabolism have attracted interest as 
targets of drug intervention, and spa-
therapy can influence the serum levels 
of several cytokines. We investigated 
the effects of spa-therapy on clinical 
and ultrasonographic (US) findings 
and serum levels of cartilage oligomer-
ic matrix protein (COMP) and several 
cytokines, chemokines, and growth fac-
tors in a prospective cohort of patients 
with symptomatic knee OA.
Methods. Patients (n=53) with prim-
ary symptomatic knee OA were treated 
for 12 consecutive days with locally 
applied mud-packs. Assessments were 
made at baseline, immediately after 
completion of the treatment cycle, and 
6 and 12 months after completion of 
treatment. They included visual ana-
logue scale (VAS) ratings of pain, the 
Lequesne algofunctional index for knee 
OA, and US with calculation of a semi-
quantitative score that expressed the 
severity of the local inflammatory proc-
ess. Serum levels of 27 cytokines (in-
cluding interferon-γ-inducible protein-
10 [IP-10]), chemokines, and growth 
factors were measured with multiplex 
bead-based immunoassays, and COMP 
levels were determined by ELISA.
Results. US scores, VAS pain ratings, 
and Lequesne indexes indicated sig-
nificant improvement after spa-therapy 
and at the 6- and 12-month follow-ups. 
Serum IP-10 levels also dropped signif-
icantly (p=0.0035), and this reduction 
was positively correlated with improve-
ment of the Lequesne index (p=0.031).
Conclusions. In patients with knee OA, 
spa-therapy can modulate serum levels 
of proinflammatory cytokines/chemok-
ines and produce improvements in joint 
pain and function that persists for up 
to 1 year.
Introduction
Osteoarthritis (OA) is a chronic rheu-
matic disease characterised by the pro-
gressive and frequently disabling de-
struction of articular cartilage (1). Bio-
mechanical and biochemical aspects of 
the local milieu lead to chondrocyte ac-
tivation and disruption of homeostasis 
(2). Several chemokines, cytokines, and 
growth factors have already been impli-
cated in the inflammation and cartilage 
degradation associated with OA, influ-
encing the metabolic state of chondro-
cytes. In the local milieu, the imbalance 
between pro- and anti-inflammatory cy-
tokines may determine the progression 
of cartilage damage (3-5). 
According to recent findings, pro-in-
flammatory cytokines such as the re-
cently described interferon-γ-inducible 
protein-10 (IP-10), may be responsible 
for the synovial-cell and chondrocyte 
responses that ultimately cause tis-
sue-damage in OA. Interest is also in 
the cartilage oligomeric matrix protein 
(COMP) that was found at increased 
serum levels in patients with severe, 
active OA correlating with radiograph-
ic progression of joint damage. Thus, 
modulation of chondrocyte activity 
and metabolism has attracted growing 
interest as potential mechanisms for 
novel anti-OA drug therapies. Previous 
studies have shown spa-therapy to af-
fect serum levels of several cytokines 
(6). Although spa-therapy is not in-
cluded among those recommended by 
the European League against Rheuma-
tism (EULAR) for OA, it is one of the 
most frequently prescribed and it could 
provide beneficial effects lasting up 
to 6 months (7, 8). In this prospective 
cohort study, we investigated the short- 
and longer-term influence of spa-thera-
py on sonographic findings in knee OA, 
as well as on clinical manifestations 
and serum levels of several cytokines, 
chemokines and growth factors. 
Materials and methods
We consecutively enrolled 53 patients 
with primary OA of one or both knees 
diagnosed according to the clinical and 
radiographic criteria of the American 
College of Rheumatology (9). Inclu-
sion and exclusion criteria were previ-
ously described in Forestier et al. (8). 
Patients were also excluded if they had 
received non-steroidal anti-inflamma-
tory drugs or other analgesics within 
the 2 days before enrolment. 
Demographic data, histories, and clini-
cal data of each participant were re-
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corded on standardised forms. A com-
plete physical examination and rheu-
matologic evaluation was performed by 
the same physician before the patient 
initiated spa-therapy. Spa-therapy con-
sisted of a total of 12 daily mud-pack 
applications to the knee(s) at the Tivoli 
Terme Spa in Italy. Patients were treat-
ed after an overnight fast. A 10-cm lay-
er of “mature” thermal mud (40°C) was 
applied to the affected knee(s). Twenty 
minutes later, the mud was removed, 
and the knee was bathed for 10-12-min 
in warm water (37–38°C) (10). Each 
patient was re-evaluated (as described 
above) after the end of the 12-treatment 
cycle, and 18/53 were also evaluated 
after 6 and 12 months.
Pain was assessed with a 100-mm 
visual analogue scale (VAS), and the 
Lequesne algofunctional index was 
used to measure the severity of the 
patient’s knee OA (11). Each patient 
underwent ultrasonographic (US) ex-
aminations of both knees performed by 
a rheumatologist experienced in sonog-
raphy. Examinations were carried out 
in accordance with EULAR guidelines 
for ultrasonography in rheumatology 
(12) with a Philips/HP Image Point HX 
scanner and a 10-MHz linear probe. 
Sonographic signs of synovitis (syno-
vial hypertrophy and joint effusion) 
were recorded, and vascularisation of 
the synovial membrane was assessed 
with power Doppler (pD) (settings: 
prf 1000 Hz, gain 18-30 db, low fil-
ter). Synovial hypertrophy and syno-
vial fluid were defined in keeping with 
Outcome Measures in Rheumatoid Ar-
thritis Clinical Trials (OMERACT) rec-
ommendations (13), observed on grey-
scale and scored according to severity 
(0 to 3). Perfusion revealed by pD was 
scored according to intensity (0 to 3). 
The presence or absence of a Baker’s 
cyst was indicated respectively with a 
score of 1 or 0. The sum of these scores 
(total US score) (range 0-10), was used 
as an indicator of global change of sin-
gle joint score; the sum of the single-
joint scores was used as an indicator of 
total joint involvement in each patient 
(range 0-20) (14).
Blood samples for laboratory assays 
were collected 30 min before the first 
mud-pack, 2 h after the last one. Com-
mercially available multiplex bead-
based immunoassay kits (Human 27-
plex, Bio-Rad laboratories, Hercules, 
CA) were used to measure concentra-
tions of interleukine (IL)-1Β, IL-1RA, 
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, 
IL-10, IL-12, IL-13, IL-15, IL-17, eotax-
in, basic fibroblast-growth factor (FGF-
Basic), granulocyte-colony stimulating 
factor (G-CSF), granulocyte monocyte-
CSF, interferon-γ, IP-10, monocyte che-
moattractant protein-1 (MCP-1), mac-
rophage-inhibiting protein-1α and 1β 
(MIP-1α and MIP-1β),  platelet-derived 
growth factor (PDGF), regulated on ac-
tivation normal t cell expressed and se-
creted (RANTES), tumor necrosis fac-
tor-α, and vascular endothelial growth 
factor (VEGF). Assays were performed 
according to the manufacturer’s instruc-
tions. Each sample was assayed in du-
plicate. Briefly, the appropriate cytokine 
standards and samples diluted in serum 
diluents (50 μl/well) were added to a 
96-well filter plate and incubated for 
30 min at room temperature. Following 
washes, premixed streptavidin-phyco-
erythrin was added to each well and in-
cubated for 10 min. After 3 more wash-
es, the beads were resuspended in 125 
ml of assay buffer, and the cytokines 
in the reaction mixture were quantified 
with the Bio-Plex protein array reader. 
Data were analysed with Bio-Plex man-
ager software, version 4.1.1 (Bio-Rad 
laboratories). Values with a coefficient 
of variation >12% were excluded from 
the final data analysis. The concentra-
tions (pg/ml) of different analytes in the 
plasma samples were determined with 
the aid of standard curves generated in 
the multiplex assays. Serum COMP lev-
els were measured with a commercially 
available ELISA kit (Wieslab Hcomp 
quantitative kit, Euro-diagnostica, 
Malmö, Sweden).
Statistical analysis
Data were analysed with Wilcoxon’s 
matched pairs test and paired t-test. 
Analyses were carried out with version 
13.0 of the Statistical Package For So-
cial Sciences, Chicago, IL, USA. Bon-
ferroni correction was performed for 
multiple comparisons (pc). Spearman’s 
test was used for correlations. Data are 
expressed as means±SD or means and 
ranges. Only two-tailed p-values <0.05 
were considered significant.
Results
At baseline, the 53 patients with knee 
OA had a mean US score of 4.1±2.7 
(range 0-13), a mean VAS pain rating 
of 52.6±16.4 mm (range 18-90 mm), 
and a mean Lequesne index of 9.5±4.5 
(range 1.5-19). Shortly after comple-
tion of spa-therapy, all 53 patients dis-
played statistically significant improve-
ment in all 3 parameters, as shown in 
figure 1. In the 18 patients with 6- and 
12-month follow-up data, clinical and 
US improvement persisted compared 
with baseline and end-of-treatment 
findings (Fig. 1). 
Comparison of baseline and end-of-
treatment laboratory findings revealed 
a statistically significant decrease in 
IP-10 levels after spa-therapy (base-
line 849±485 pg/ml versus 662±417 
pg/ml after spa-therapy, p=0.0035, 
pc=0.021). These changes were posi-
tively correlated with improvements in 
the Lequesne index (Spearman’s test) 
(p=0.031). COMP levels also dropped 
after spa-therapy, but this change was 
not significant (baseline 20.0±5.3 pg/
ml versus 18.8±5.4 pg/ml after spa-
therapy, p=NS). Serum levels of the 
other cytokines, chemokines, and 
growth factors analysed were not sig-
nificantly different after spa-therapy 
(data not shown). 
Discussion
OA has generally been considered a 
non-inflammatory degenerative dis-
ease, but recent findings indicate that 
several stages of the disease can be 
associated with inflammatory chang-
es sustained by cytokine storms and 
growth-factor release (15, 16). 
In our cohort of 53 patients with knee 
OA, spa-therapy significantly reduced 
pain and disease activity as measured 
by VAS and the Lequesne index. This 
improvement was also accompanied 
by a decrease in the US score and by 
changes in chemokine and cytokine se-
rum levels that included significant de-
creases in IP-10, which displayed posi-
tive correlation with clinical changes. 
These preliminary results, although in 
a relatively small cohort, represent an 
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exploratory data analysis to assess the 
efficacy of spa-therapy alone in knee 
OA and relations with US findings and 
serum cytokines levels. 
One of the most promising imaging in 
OA techniques is US, which represents 
a simple, widely available tool for 
detecting joint effusion and synovial 
thickening, as recently reported in the 
EULAR evidence-based recommenda-
tions for the diagnosis of knee OA (evi-
dence level: I-b) (17, 18). In our study, 
we used US to monitor the response to 
spa-therapy in patients with knee OA 
patients. Results were maintained at 
12 months, suggesting that spa-therapy 
may also have positive effects in terms 
of the control of disease progression.
IP-10 is a pro-inflammatory chemok-
ine (19, 20) that regulates immune re-
sponses by activating and recruiting 
lymphocytes into the joint and plays 
roles in leukocyte homing in inflamed 
tissues. Recent reports have shown that 
serum and/or tissue levels of IP-10 are 
increased in various autoimmune/in-
flammatory diseases such as rheuma-
toid arthritis. The observed significant 
decrease in IP-10 levels after spa-thera-
py may result in reduced pro-inflamma-
tory stimuli and the positive correlation 
with clinical improvement suggests a 
pathological role for IP-10 in knee OA. 
Serum COMP levels have been pro-
posed as a molecular marker of carti-
lage damage in OA, and these levels 
displayed correlation with radiographic 
progression of joint damage (21). Even 
if we observed a reduction in mean 
COMP levels after spa-therapy, such 
reduction did not correlate with US 
findings. 
In conclusion, the spa-therapy evaluat-
ed in this OA cohort produced substan-
tial clinical improvement. Further stud-
ies are needed to clarify the potential 
effects of Spa therapy on the cytokine 
profile of OA patients.
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